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Purpose:

To evaluate short-acting bronchodilator effects in chronic obstructive pulmonary disease (COPD) by using hyperpolarized
helium 3 (3He) magnetic resonance (MR) imaging, spirometry,
and plethysmography.

Materials and
Methods:

Fourteen ex-smokers with COPD provided written informed consent to a local ethics board–approved and Health Insurance and
Portability Accountability Act–compliant protocol and underwent
hyperpolarized 3He and hydrogen 1 MR imaging, spirometry, and
plethysmography before and a mean of 25 minutes 6 2 (standard
deviation) after administration of 400 mg salbutamol. Distribution
of 3He gas was evaluated by using semiautomated segmentation of
3
He voxel intensities, where cluster 1 represented regions of signal
void or ventilation defect volume (VDV), and clusters 2–5 (C2–C5)
represented gradations of signal intensity from hypointensity (C2)
to hyperintensity (C5). 3He ventilation defect percentage (VDP)
was calculated as VDV normalized to the thoracic cavity volume.
Comparisons of pre- and post-salbutamol means were performed
by using a two-way mixed-design repeated measures analysis of
variance, and comparisons of the magnitude of the treatment effect
between pulmonary function and 3He MR imaging measurements
were performed by using effect size (ES) calculations. The relationships between pulmonary function and 3He MR imaging findings
were determined by using Spearman correlation coefficients.

Results:

After salbutamol administration, there were significant changes
in forced expiratory volume in 1 second (FEV1) (P = .001),
total lung capacity (P = .04), and functional residual capacity
(P = .03), as well as VDP (P , .0001) and 3He gas distribution
(C2, P = .01; C3, P = .03; C4, P , .0001; and C5, P = .02). Treatment ES was greater for 3He VDP than for FEV1 (0.50 vs 0.22).
There was a significant correlation between baseline VDP and
post-salbutamol FEV1 change (r = 20.77, P = .001). Although five
patients were classified as bronchodilator responders and nine
patients were classified as bronchodilator nonresponders according to American Thoracic Society and European Respiratory Society criteria, there was no significant difference in the magnitude
of the 3He MR imaging changes after salbutamol administration
between responder groups.
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Conclusion:

3

He MR imaging depicted significant improvements in the distribution of 3He gas after bronchodilator therapy in ex-smokers
with COPD with and those without clinically important changes
in FEV1.
q
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C

hronic obstructive pulmonary disease (COPD) is characterized by
progressive expiratory flow limitation that develops because of the combined effects of large and small airway
dysfunction and increased lung compliance related to the permanent destructive changes of emphysema (1). Gas trapping and dynamic lung hyperinflation
are major consequences of decreased
expiratory airflow and often lead to many
of the disabling symptoms associated
with COPD, such as dyspnea and limitation of exercise capacity (2,3). After
smoking cessation, bronchodilators are
the first-line therapy in the symptomatic
management of COPD (3), and assessment of acute response to bronchodilators is often based on spirometric measurements of forced expiratory volume
in 1 second (FEV1). Although spirometric
measurements provide the most common primary end point for clinical trials
evaluating therapeutic response, relatively poor correlations have been reported between FEV1 and other clinical
measurements of COPD (4–6). In other
words, symptomatic relief after bronchodilator use often occurs with only
modest improvements in FEV1 (7–9),
underscoring the apparent discordance
between spirometric measurements and
COPD symptoms, quality of life, and
functional measurements.
The discordance between spirometric measurements and COPD symptoms,

Advances in Knowledge
n Helium 3 (3He) MR imaging measurements of gas distribution
showed significant improvements
(P , .0001) after salbutamol
administration in ex-smokers
with chronic obstructive pulmonary disease (COPD), providing
evidence of the regional and
physiologic effects of therapy.
n Significant improvements (P ,
.0001) in 3He gas distribution
after bronchodilator administration were detected by using
hyperpolarized 3He MR imaging in
COPD, regardless of spirometrybased bronchodilator response
classification.
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as well as the limitation of standard
measures of expiratory airflow for evaluating the regional nature of bronchodilator response, is motivating the evaluation of new methods (10,11), including
those based on noninvasive imaging
(12–15). For example, computed tomography (CT) has been used to evaluate
changes in airway morphology after administration of salbutamol (12,13) and
tiotropium (14,15) and showed greater
post-bronchodilator response in patients
with COPD with mainly airway disease
compared with those with mainly emphysema (16). Additionally, a recent single photon emission computed tomography/CT and multiple breath nitrogen
washout study (17) reported no significant change in ventilation heterogeneity
after tiotropium administration.
Pulmonary magnetic resonance (MR)
imaging with hyperpolarized helium 3
(3He) has emerged as a functional imaging method that provides high-spatialresolution and high-temporal-resolution
(18–23) images of the lung. Regional ventilation abnormalities are clearly visualized as areas of decreased 3He signal in
the lung that can be scored or quantified with the metric ventilation defect
percentage (VDP) (19) or percentage
ventilated volume (24). 3He MR imaging ventilation abnormalities have previously been evaluated in COPD (25–30)
with measurements that are sensitive to
the pathologic changes that accompany
COPD (24), have high same-day and
short-term reproducibility (20,21), and
reveal significant longitudinal changes
over 2 years before changes in FEV1
are observed (18). Because of previous
reproducibility (20,21) and longitudinal
(18) findings, we hypothesized that 3He

Implication for Patient Care
n Our results indicate that significant gas distribution improvements occur even in patients with
COPD with minimal forced expiratory volume in 1 second or
forced vital capacity response to
salbutamol; these findings are
relevant to our understanding of
the regional and functional
effects of bronchodilators.

MR imaging would provide the necessary and sufficient spatial and temporal sensitivity, as well as precision,
to depict any potential regional functional lung changes after bronchodilator therapy. Therefore, our aim was
to evaluate short-acting bronchodilator
effects in COPD by using hyperpolarized 3He MR imaging, spirometry, and
plethysmography.

Materials and Methods
Patients
All patients provided written informed
consent to the study protocol, which was
approved by the local research ethics
board and Health Canada, and the study
was compliant with the Personal Information Protection and Electronic
Documents Act of Canada and the
Health Insurance Portability and Accountability Act of the United States.
The use of an on-site 3He gas polarizer
(HeliSpin; GE Healthcare, Durham, NC)
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GOLD = Global Initiative for Chronic Obstructive Lung
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SaO2 = arterial oxygen saturation
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was provided to Robarts Research Institute through an agreement with GE
Healthcare for which we pay $100 000
Canadian annually.
Fourteen patients with a clinical diagnosis of COPD who were ex-smokers
with a smoking history of at least 10
pack-years and who had Global Initiative
for Chronic Obstructive Lung Disease
(GOLD) stage II–IV disease were enrolled. Patients were required to refrain
from using both short-acting and longacting bronchodilators on the morning
of the study. Prebronchodilator MR imaging was performed immediately after
pulmonary function testing; postbronchodilator MR imaging and pulmonary
function testing were performed a mean
of 25 minutes 6 2 (standard deviation)
after administration of 400 mg salbutamol sulfate USP (Apo-Salvent CFC Free
Inhalation Aerosol; Apotex, Toronto,
Ontario, Canada), which was inhaled by
using a spacer device.

Pulmonary Function Testing
Spirometry was performed using an
EasyOne spirometer (ndd Medizintechnik,
Zurich, Switzerland) according to the
American Thoracic Society (ATS) guidelines. Static lung volumes and diffusing capacity of lung for carbon monoxide (DLCO) were measured by using
body plethysmography (MedGraphics,
St Paul, Minn).
Image Acquisition
MR imaging was performed with a wholebody 3.0-T MR imaging system (Excite
12.0; GE Healthcare, Milwaukee, Wis)
with broadband imaging capability as
previously described (21), and 3He MR
imaging was enabled by using a singlechannel rigid elliptical transmit-receive
chest coil (RAPID Biomedical, Wuerzburg, Germany). It is important to note
that we endeavored to minimize the
potential for differences in the levels
of inspiration between the breath-hold
acquisitions for each patient by (a) conducting training and practice sessions
for all patients before MR imaging related to the inspiration breath-hold maneuver from functional residual capacity
(FRC) and (b) continuous coaching and
monitoring at the MR imaging table by a
Radiology: Volume 261: Number 1—October 2011
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pulmonary function technologist during
all inspiration breath-hold acquisitions.
Because of this extensive coaching, no
correction for differences in inspiration
levels between breath-hold acquisitions
for individual patients was required.
Pulse oximetry was used to measure
arterial oxygen saturation (SaO2) for all
patients during imaging sessions; an
adverse event was considered to have occurred when SaO2 decreased below 88%
at any time during the imaging session.
Study withdrawal was required when
SaO2 decreased to 80% for 10 seconds
or longer.
Conventional hydrogen 1 (1H) MR
imaging was performed before hyperpolarized 3He MR imaging, with patients
imaged during a 1.0-L breath-hold of
4
He/nitrogen 2 (N2) by using a wholebody radiofrequency coil and a 1H fast
spoiled gradient-recalled echo sequence
(total data acquisition time, 16 seconds; repetition time msec/echo time
msec, 4.7/1.2; flip angle, 30°; field of
view, 40 3 40 cm; matrix, 256 3 128;
14 sections; 15-mm section thickness;
no gap), as previously described (21).
Prior to 3He MR imaging, a polarizer
system (HeliSpin; GE Healthcare) was
used to polarize 3He gas to 30%–40%,
and doses of 5 mL per kilogram of body
weight, diluted with ultra–high purity
medical-grade nitrogen (Spectra Gases,
Alpha, NJ), were administered in 1.0-L
Tedlar bags. As previously described
(21), hyperpolarized 3He coronal static
ventilation images were acquired during a breath-hold of a 1.0-L 3He/N2 mixture (total data acquisition time, 14 seconds; 4.3/1.4; flip angle, 7°; bandwidth,
31.25 kHz; field of view, 40 3 40 cm;
matrix, 128 3 128; 14 sections; 15-mm
section thickness; no gap).

Image Analysis
Semiautomated segmentation of 3He
pulmonary ventilation MR images was
performed by using custom software that
had been generated by using MATLAB
R2007b (Mathworks, Natick, Mass), as
previously described (31). Briefly, and
as shown in the schematic in Figure 1,
3
He MR images were evaluated by using
k-means cluster analysis (32), similar
to previously described methods for 3He

radiology.rsna.org
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MR image segmentation (33–35), to classify the 3He MR imaging voxel intensity
values into clusters ranging from 1 to 5,
representing gradations of signal intensity from no signal (cluster 1) and hypointense signal (cluster 2) to hyperintense signal (cluster 5) and generating
a 3He voxel cluster map (Fig 1b). To obtain the external contour of the thoracic
cavity to differentiate ventilation defects
(cluster 1) from the edge of the lung, 1H
MR images were segmented by using a
seeded region-growing algorithm (36)
and were registered to the 3He MR ventilation images as previously described
(37). VDP was generated by using VDV,
or cluster 1, normalized to the thoracic
cavity volume as previously described
(19). For the remaining ventilation clusters, the segmented 1H thoracic cavity
volume was used to generate a cluster
percentage representing a normalized
3
He cluster volume for the lung. All
measurements were performed by the
same observer (M.K., with 3 years of
experience performing manual 3He MR
image segmentation and 1 year of experience developing and performing
semiautomated 3He MR image segmentation), who was blinded to patient and
time point, with time point randomized to reduce any potential measurement bias. Reproducibility of the semiautomated method was determined
on the basis of the pre-salbutamol intraobserver variability of five repeated measurements for five patients with COPD.
The smallest detectable difference (SDD),
or the minimum change in 3He measurements that could be measured confidently in individual patients—not due
to observer measurement variability, for
five of the patients with COPD was 2%
for VDP and 0.4%, 1%, 0.6%, and 0.3%
for clusters 2–5, respectively.

Statistical Analysis
Multivariate analysis of variance and
repeated-measures analysis of variance
were performed for comparison of preand post-salbutamol pulmonary function
and lung volume measurements by using
software (SPSS, version 16.0; SPSS,
Chicago, Ill). A two-way mixed-design
analysis of variance was used (with SPSS)
to determine the interactions between
285
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Figure 1

Pulmonary Function Measurements
Table 2 shows mean pulmonary function
and 3He MR imaging measurements
for all patients, and Table E1 (online),
provides a per-patient list of all measurements. Statistically significant postsalbutamol changes were observed
for FEV1 (P = .001, ES = 0.22), TLC
(P = .04, ES = 20.34), and FRC (P = .03,
ES = 20.10).

Figure 1: A, Coronal 3He MR image and, B, 3He cluster map generated with semiautomated cluster analysis and segmentation for all sections. 3He ventilation defect volume ( VDV ) = cluster 1, while VDP = cluster 1
normalized to thoracic cavity volume.

patients and treatment, imaging section
and treatment, and bronchodilator response group and treatment for all 3He
MR imaging measurements. Effect size
(ES) calculations allowed the magnitude
of an effect to be compared between
disparate types of measurements (38).
Therefore, for comparison of the magnitude of the treatment effect between
pulmonary function and imaging measurements, treatment ES was calculated
as the ratio of the mean difference between pre- and post-salbutamol measurements and the pooled standard deviation for all patients, calculated by using
Hedges g as shown in Equation (1):

g

xpost  xpre
(npost  1)SDpost 2  (npre  1)SDpre 2

, (1)

npost  npre  2

where xpre and xpost are the mean preand post-salbutamol measurement for
all patients, SDpre and SDpost are the
standard deviations of the pre- and postsalbutamol measurements for all patients, and npre and npost are the numbers
of patients evaluated before and after
salbutamol administration. The SDD,
defined as the smallest difference that
can be measured with prospectively
determined confidence that is not due
to measurement error (variability), was
calculated for five repeated pre-salbutamol
3
He VDP measurements according to
286

the method of Eliasziw et al (39), as
shown in Equation (2):
SDD t zD 2SEMintra,

(2)

where za is 1.96, corresponding to a
significance level of a = .05, and SEMintra
is the standard error of measurement
due to intraobserver variability and is
calculated as shown in Equation (3):
SEMintra

Vˆ e 2 ,

(3)

where Vˆ e2 is the intraobserver repeatedmeasures variance. Linear regression
(r2 values) and Spearman correlation
coefficients (r values) were calculated
to determine the relationships between
pulmonary function and 3He MR imaging measurements by using software
(Prism, version 4.0; GraphPad Software,
San Diego, Calif). In all statistical analyses, results were considered significant
when the probability of making a type I
error was less than 5% (P , .05).

Results
Patient Demographics
Patient demographic characteristics are
provided in Table 1 for 14 ex-smokers
with COPD (five with GOLD stage II
disease, eight with GOLD stage III disease, and one with GOLD stage IV
disease).

Imaging Measurements
Figure 2 shows two central coronal 3He
MR imaging sections, on which the trachea and two main bronchi are clearly
visible and 3He ventilation is displayed in
red, registered to the gray-scale 1H MR
images of the thorax for each of the five
representative patients (two patients with
GOLD stage II disease, two patients with
GOLD stage III disease, and one patient
with GOLD stage IV disease) before and
after salbutamol administration. To ensure that the increased distribution of
3
He gas after salbutamol administration was not due to differences in the
volume of polarized gas administered at
each time point, we calculated the total
pixel intensity for each lung image, including the trachea and major airways,
from the image pixel intensity frequency
histograms, as well as the total moles of
polarized gas delivered for each patient
time point (data not shown). These estimations showed that the amount of
polarized gas administered and inhaled
was not significantly different between
time points (P = .87). The signal-to-noise
ratio for each pre- and post-salbutamol
image pair was also not significantly
different (P = .12). To minimize the
potential of introducing intensity variations because of B1 field inhomogeneity,
patients were located in the same position within the coil between imaging
time points.
Table 2 shows mean normalized
pre- and post-salbutamol 3He measurements, and Table E2 (online) shows
the mean pre- and post-salbutamol 3He
volume and signal intensity measurements. There was a significant decrease
in VDP after salbutamol administration
(P , .0001, ES = 20.50), and there was
no relationship between post-salbutamol changes in VDP and image section

radiology.rsna.org
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Table 1
Demographic Data in 14 Patients
Parameter

Datum

Age (y)
Men
Women
No. of men
Body mass index (kg/m2)
FEV1 (L)
FEV1*
FVC (L)
FVC*
FEV1/FVC
TLC (L)
TLC*
Inspiratory capacity (L)
Inspiratory capacity*
FRC (L)
FRC*
Reserve volume (L)
Reserve volume*
DLCO*

70 6 6 (61–77)
70 6 6 (61–77)
71 6 6 (64–77)
8
24.9 6 3.8 (17.6–31.4)
1.23 6 0.50 (0.63–2.18)
45 6 12 (28–61)
2.98 6 0.83 (1.52–4.44)
83 6 12 (65–107)
41 6 10 (22–60)
7.12 6 1.27 (4.82–8.96)
122 6 20 (101–175)
2.21 6 0.54 (1.39–3.09)
83 6 16 (58–108)
4.89 6 1.22 (3.14–7.27)
155 6 42 (110–243)
3.83 6 0.94 (2.63–5.25)
170 6 53 (104–285)
43 6 19 (20–89)

Note.—Unless otherwise specified, data are means 6 standard deviations, with ranges in parentheses. FVC = forced vital
capacity, TLC = total lung capacity.
* Data are percentage predicted values.

Table 2
Pre- and Post-Salbutamol Measurements in 14 Patients
Parameter
Pulmonary function measurement (L)
FEV1
FVC
TLC
Inspiratory capacity
FRC
Reserve volume
Hyperpolarized 3He MR imaging
measurement (%)
VDP
Cluster 2
Cluster 3
Cluster 4
Cluster 5

Pre-Salbutamol

Post-Salbutamol

1.23 6 0.50
2.98 6 0.83
7.05 6 1.22
2.15 6 0.58
4.89 6 1.22
3.79 6 0.91

1.35 6 0.57)
3.06 6 0.85)
6.62 6 1.26†
2.02 6 0.66†
4.61 6 1.22†
3.59 6 0.85†

28 6 7
15 6 2
31 6 5
19 6 4
863

24 6 9
14 6 2
32 6 5
22 6 5
963

P Value*

ES

.001
.46
.04
.39
.03
.23

0.22
0.10
20.35
20.21
20.23
20.23

,.0001
.01
.03
,.0001
.02

20.50
20.50
0.20
0.66
0.33

Note.—Unless otherwise specified, data are means 6 standard deviations.
* Calculated with repeated-measures analysis of variance for the pulmonary function measurements and two-way mixed-design
repeated-measures analysis of variance for the MR imaging measurements.
†

Available for 13 patients.

(as a region of interest) (P = .30), indicating no bias for any measurable
changes with respect to image section.
After salbutamol administration, there
Radiology: Volume 261: Number 1—October 2011
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was a significant decrease in 3He cluster 2 (P = .01, ES = 20.50) and significant increases in 3He cluster 3 (P = .03,
ES = 20.20), cluster 4 (P , .0001,

radiology.rsna.org

ES = 20.66), and cluster 5 (P = .02, ES =
20.33). On the basis of pre-salbutamol
intraobserver variance, the SDD, or the
minimum change in 3He measurements
that could be measured confidently in
individual patients that was not due
to observer measurement variability,
for five of the patients with COPD (one
with stage II disease and four with stage
III disease) was 2% for VDP and 0.4%,
1%, 0.6%, and 0.3% for clusters 2–5,
respectively.
As shown in Figure 3, there were
significant and moderate Spearman correlations between baseline 3He VDP and
post-salbutamol changes in FEV1 (r =
20.77, P = .001) and between baseline
FEV1 as a percentage predicted value
and post-salbutamol changes in FEV1 (r =
0.56, P = .04). There was also a significant correlation between the changes
measured in 3He cluster 2 and changes
in FEV1 (r = 20.62, P = .02) and FVC
(r = 20.59, P = .03).

Bronchodilator Responders and
Nonresponders
Published ATS and European Respiratory Society guidelines (40) define a significant bronchodilator response as an
increase in post-salbutamol FEV1 and/or
FVC greater than 200 mL and 12%.
Accordingly, five patients were classified
as bronchodilator responders and nine
patients were classified as bronchodilator
nonresponders. As shown in Table 3 and
Table E1 (online), mean reductions in
VDP and cluster 2 and corresponding
increases in clusters 3–5 were demonstrated for both responders and nonresponders. As shown in Figure 4, VDP
was significantly lower for responders
than for nonresponders at baseline and
after bronchodilator administration (P =
.03). As depicted by the parallel slopes for
pre- and post-salbutamol measurements
shown in Figure 4, there was no significant difference between responders
and nonresponders for post-salbutamol
change at 3He MR imaging (VDP, clusters 2–5, P . .05). It is important
to point out that there was a single
nonresponding patient who showed a
240-mL and 12% improvement in FEV1
(just missing the . 12% change in
FEV1 requirement for bronchodilator
287
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Figure 2

Figure 2: Pre- and post-salbutamol 3He MR images (in red) registered to two center coronal thoracic 1H MR images (in gray
scale) for five representative patients with COPD. The patients in S1 and S2 had GOLD stage II disease, the patients in S3
and S4 had GOLD stage III disease, and the patient in S5 had GOLD stage IV disease. The change in 3He gas distribution after
salbutamol is readily apparent in the right and left apical regions in S1 and S5 and in the right mid-apical region in S3, whereas
there is little change visible in S2 and S4 for the two sections shown.

response), and when this patient
was recategorized as a responder, the
reported results remained the same.
It is also worth noting that there were
no significant differences between responders and nonresponders in terms
of baseline FEV1 (P = .44) or DLCO
(P . .99).
288

Discussion
In this pilot functional MR imaging
evaluation of bronchodilator effects in
COPD, we made a number of observations and report the following: (a) significant postbronchodilator improvements
in both spirometric and 3He MR imaging

measurements of gas distribution and
their effect sizes, (b) a significant relationship between 3He VDP and changes
in FEV1 after salbutamol administration,
and (c) changes at 3He MR imaging after
bronchodilator administration that were
not significantly different for responder
and nonresponder subgroups.

radiology.rsna.org

n

Radiology: Volume 261: Number 1—October 2011

THORACIC IMAGING: Quantifying Bronchodilator Effects in COPD with 3He MR Imaging

Kirby et al

Figure 4

Figure 3

Figure 3: Graphs show correlation between (a) baseline (BL) FEV1 as percentage predicted value (%pred )
and post-salbutamol change in FEV1 (in liters) and (b) baseline VDP and post-salbutamol change in FEV1. (a)
Baseline FEV1 is significantly correlated with DFEV1 (r = 0.60, r 2 = 0.36, P = .02, y = 0.006 · 20.13) and
(b) baseline VDP is significantly correlated with DFEV1 (r = 20.68, r 2 = 0.46, P = .008, y = 20.01 · +0.42).
Dotted lines = 95% confidence intervals.

First, and as might be expected
from previous work that demonstrated
modest improvements in lung function
in patients with COPD after bronchodilator therapy (7,10,11,41–43), we observed statistically significant changes in
mean FEV1, FRC, and TLC. At the same
time, significant decreases in 3He MR

imaging VDP and cluster 2 and significant improvements in 3He MR imaging
clusters 3–5 were measured, suggesting
regional gas distribution improvements
throughout the lung. Additionally, the
3
He gas distribution changes occurred in
different sections for each patient, with
no detected bias for specific regions

Figure 4: Graph shows mean changes in 3He VDP
for bronchodilator responders (black line) and nonresponders (gray line). Values are means calculated
for all patient imaging sections, and error bars =
95% confidence intervals.

of gas distribution improvements. This
finding is in agreement with those of a
recent CT study (15) that demonstrated
regionally dispersed airway wall structural alterations after bronchodilator
administration. Moreover, when ES was

Table 3
Per-Patient Changes in Spirometric and 3He MR imaging Measurements after Salbutamol Administration
3

Spirometry
Patient Group and No.
All Patients
Responders
Patient 1
Patient 3
Patient 5
Patient 7
Patient 10
All
Nonresponders
Patient 2
Patient 4
Patient 6
Patient 8
Patient 9
Patient 11
Patient 12
Patient 13
Patient 14
All

DFEV1*

DFVC*

DVDP (%)

DCluster 2 (%)

He MR Imaging

DCluster 3 (%)

DCluster 4 (%)

DCluster 5 (%)

0.12/10

0.07/2

24

21

1

3

1

0.14/11
0.18/16
0.32/15
0.18/25
0.27/22
0.22/11

0.46/14
0.42/13
0.36/10
0.24/16
0.49/21
0.36/14

2
2
214
0
211
24

21
21
22
1
24
21

21
0
2
1
4
1

0
0
9
0
6
3

0
22
5
21
4
1

0.02/2
0.04/6
0.00/0
20.06/27
0.24/12
0.08/9
0.06/8
0.13/9
0.07/4
0.06/5

20.01/0
20.25/211
20.32/212
20.07/23
0.35/9
0.11/3
20.08/24
0.07/2
20.76/217
20.11/23

0
2
3
26
22
28
220
23
26
25

0
21
21
23
0
0
22
21
1
21

1
0
22
3
22
25
10
21
7
1

0
21
0
5
2
9
10
2
0
3

21
21
21
1
2
4
2
3
22
1

Note.—Significant bronchodilator response was defined as an increase in FEV1 and/or FVC greater than 200 mL and 12% from pre-salbutamol values according to ATS/ European Respiratory Society
guidelines (40).
* Data are liters/percentage change from baseline absolute value in liters.
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evaluated, which allows the magnitude of
the treatment effect to be compared between disparate types of measurements,
3
He MR imaging measurements provided
greater ES than FEV1. We also observed
an overall mean change in VDP and all
3
He ventilation cluster measurements
greater than the SDD, indicating that
the measured improvement in 3He distribution after salbutamol administration was not due to measurement error
or lack of reproducibility. Although this
study did not include a control arm, it
is important to note that 11 of the 14
patients evaluated here previously participated in a reproducibility study (20)
approximately 2 years prior to the preand post-salbutamol imaging in this
study. In that previous study, the mean
change in VDV for these patients, approximately 7 minutes after imaging,
was 1 mL—not a significant or clinically
relevant change. For the same 11 patients
reported here, the mean change in 3He
VDV (cluster 1) was 62 mL. Taken
together, these results strongly suggest
that the changes after treatment observed
here were not due to either scan-rescan
variability or the intraobserver variability of the measurement technique. We
must also point out that although, to
our knowledge, this is the first reported
study demonstrating improvements in
3
He gas distribution after bronchodilator
therapy in COPD, previous 3He MR imaging studies have demonstrated changes
in 3He gas distribution after bronchial
provocation tests with methacholine in
asthma and after therapy in patients
with cystic fibrosis (25–29). Taken together, results of these imaging-based
treatment response studies indicate that
functional MR imaging may be considered
for evaluating new respiratory therapies
in clinical trials.
Second, we also observed a significant negative correlation between baseline VDP and changes in FEV1 after
salbutamol administration, as well as a
significant positive correlation between
baseline FEV1 and changes in FEV1.
These results suggest that patients demonstrating the greatest improvement
in FEV1 after salbutamol administration
were those with milder disease. A recent CT study (44) also evaluated a large
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number of ex-smokers with COPD as part
of the National Emphysema Treatment
Trial, and, in accordance with our MR
imaging results, demonstrated that significant bronchodilator reversibility was
more likely in patients with higher FEV1.
Finally, we detected postbronchodilator improvements in 3He VDP and
gas distribution that were not significantly different for the five responders
and nine nonresponders. On the basis
of this imaging finding, it appears that
even patients with COPD without a
clinically relevant improvement in FEV1
show improved regional gas distribution after bronchodilator administration.
In fact, both groups showed the same
mean improvement in 3He MR imaging
measurements. This important finding
suggests that measurements derived
from noninvasive imaging reveal functional lung changes that enable a better
understanding of the COPD-affected lung
and its regional response to therapy,
which may be important for drug development and drug treatment trials in COPD.
Future functional MR imaging studies
with larger sample sizes will help to confirm and extend these important findings.
We acknowledge that this pilot
study was limited by the small number
of patients examined and by the fact
that the analysis was restricted mainly
to patients with stage II and III COPD.
Therefore, caution should be exercised
in extrapolating these results to the
general COPD population and more
specifically to patients with stage I or
IV disease. Another limitation was the
lack of a true reference standard for the
measurement of treatment effects in
COPD, such as dyspnea scores and measurements of exercise tolerance for direct comparison to 3He MR imaging
measurements to evaluate the clinical
meaning of the imaging changes. In
other words, whether improvements in
gas distribution are related to clinical or
symptomatic improvement remains to
be established in a larger study. It is
also important to note that the study
patients were provided training and
instruction for inspiration breath-hold
imaging, and they performed practice
breath holds and received coaching
during breath-hold MR imaging. It is

clear for all imaging studies that standardization is required for reproducible
and comparable breath-hold volumes,
and this is critically important for acute
and chronic therapy repeated studies.
We also acknowledge that although 3He
MR imaging ventilation defect measurements have been previously reported to
have high same-day reproducibility (20)
in the majority of patients included in
this study, the prospective inclusion of a
control group would have strengthened
the conclusion that the post-salbutamol
changes observed here were directly attributable to bronchodilator treatment.
Another important consideration is the
limited access to 3He MR imaging and
the high cost of 3He gas that has thus far
restricted translation of this functional
imaging method to specialized MR physics centers. It is important to note the
development of hyperpolarized xenon
129 MR imaging, a less expensive and
more readily available approach, and a
promising alternative against which these
reported findings can be directly tested.
In conclusion, our results suggest
that noninvasive pulmonary functional
3
He MR imaging provides a way to measure acute treatment effects by quantifying 3He gas distribution before and
after therapy for COPD.
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